Novel Molecule Lotilaner Could Potentially Offer Relief to Long-suffering Demodex Blepharitis Patients

Abstract

Demodex blepharitis is a highly prevalent lid margin disease that affects approximately 25 million people in the USA, yet is often missed or misdiagnosed. Many patients experience signs and symptoms including the presence of collarettes, lid erythema, and itchy and dry eyes, and psychosocial impacts such as feeling self-conscious about their eyes, or difficulties with night-time driving or wearing make-up. There are currently no therapeutics approved by the US Food and Drug Administration to treat Demodex blepharitis, but a novel molecule, lotilaner, has demonstrated statistically significant improvements for patients.